Vonvendi or Veyvondi Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to increasing diagnosis rates of von willebrand disease, availability of recombinant protein therapies, improved clinical awareness of bleeding disorders, expansion of hospital-based hematology services, regulatory approvals for rVWF products.

The growth in the forecast period can be attributed to increasing focus on personalized rare disease treatments, rising investments in recombinant biologics, expansion of home-based infusion therapies, growing specialty pharmacy penetration, advancements in protein engineering technologies. Major trends in the forecast period include increasing use of recombinant plasma-free therapies, rising adoption of targeted bleeding disorder treatments, growing preference for on-demand bleeding management, expansion of specialty pharmacy distribution, enhanced focus on personalized hematology care.

The rising number of clinical trials is expected to drive the growth of the vonvendi or veyvondi market in the coming years. Clinical trials are research studies designed to assess the safety, effectiveness, and potential side effects of new treatments, drugs, or medical devices. The increase in clinical trials is driven by advancements in medical research and technology, the growing prevalence of chronic and complex diseases, and an aging global population that requires new treatment options. Clinical trials support vonvendi or veyvondi by providing thorough scientific evidence of their safety and effectiveness, facilitating regulatory approvals, building confidence among healthcare professionals and patients, and enabling optimized treatment protocols and wider access for managing von Willebrand disease. For example, in December 2024, a report published by the Association of the British Pharmaceutical Industry, a UK-based non-profit organization, indicated that the number of industry clinical trials initiated rose slightly from 411 in 2022 to 426 in 2023, suggesting a gradual recovery after several years. Consequently, the growing number of clinical trials is contributing to the expansion of the vonvendi or veyvondi market.

The increasing awareness of bleeding disorders is expected to drive the growth of the vonvendi or veyvondi market going forward. Bleeding disorders are medical conditions that hinder the blood's ability to clot properly, leading to excessive bleeding or difficulty stopping bleeding after an injury. The rising awareness of bleeding disorders is essential for early diagnosis, effective management, and enhanced quality of life for affected individuals, while also fostering greater understanding and support within communities and healthcare systems. Vonvendi or veyvondi aids in managing bleeding disorders, especially in individuals with von Willebrand disease, by providing a recombinant form of von Willebrand factor to enhance platelet adhesion and clot formation, thereby reducing the frequency and severity of bleeding episodes and improving control over bleeding symptoms associated with this inherited condition. For instance, in April 2025, according to Pfizer Inc., a US-based pharmaceutical and biotechnology company, the UK hemophilia A and B patient population exceeded 11,800 individuals during the 2023/24 period, highlighting a significant and clinically relevant treated population. Consequently, the growing awareness of bleeding disorders is driving the expansion of the vonvendi or veyvondi market.

Major companies operating in the von Willebrand factor replacement market are focusing on technological advancement through indication expansion and regulatory lifecycle management, including submitting and executing supplemental filings supported by extensive clinical and real-world evidence to broaden prophylactic and pediatric applications. Indication expansion and regulatory lifecycle management involve coordinated clinical, regulatory, and evidentiary activities such as pivotal or extension trials, real-world evidence generation, priority-review interactions, and updated safety-monitoring frameworks that allow a product to transition from limited, often adult-only or on-demand approvals to wider routine prophylaxis and pediatric indications, thereby increasing the clinically eligible population and transforming treatment approaches. For example, in September 2025, Takeda Pharmaceutical Company Limited, a Japan-based global biopharmaceutical company, announced that the U.S. Food and Drug Administration approved a supplemental Biologics License Application (sBLA) for VONVENDI, expanding its indication to include routine prophylaxis to reduce bleeding-episode frequency in adults with all types of von Willebrand disease (including types 1 and 2) and permitting on-demand and perioperative management of bleeding in pediatric patients. This expanded approval extends the therapy’s authorized use to more patient groups, strengthens its position as a recombinant VWF option for both adults and children, and opens new opportunities for prophylactic treatment strategies that can decrease bleeding frequency and enhance patient quality of life.

Major companies operating in the vonvendi or veyvondi market are Takeda Pharmaceutical Co. Ltd.

North America was the largest region in the vonvendi or veyvondi market in 2025. The regions covered in the vonvendi or veyvondi market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the vonvendi or veyvondi market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are influencing the vonvendi or veyvondi market by increasing costs of imported recombinant manufacturing inputs, bioprocessing equipment, sterile packaging materials, and cold-chain logistics systems. North America and Europe are particularly affected due to reliance on cross-border biologics supply chains, while Asia-Pacific faces higher production input costs for export-oriented manufacturing. These tariffs contribute to higher treatment costs and reimbursement pressures. At the same time, they encourage domestic biologics manufacturing, localized fill-and-finish operations, and long-term investments in regional biopharmaceutical infrastructure.

The vonvendi or veyvondi market research report is one of a series of new reports that provides vonvendi or veyvondi market statistics, including vonvendi or veyvondi industry global market size, regional shares, competitors with a vonvendi or veyvondi market share, detailed vonvendi or veyvondi market segments, market trends and opportunities, and any further data you may need to thrive in the vonvendi or veyvondi industry. This vonvendi or veyvondi market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Vonvendi, also known as Veyvondi, is a brand name for recombinant von Willebrand factor (rVWF), a medication used to treat and control bleeding episodes in patients with von Willebrand disease (VWD). Vonvendi is used as a therapy to manage bleeding episodes in patients with von Willebrand disease by supplementing the deficient or dysfunctional von Willebrand factor.

The main clinical indications for Vonvendi or Veyvondi include von Willebrand disease type 1, von Willebrand disease type 2, and von Willebrand disease type 3. Type 1 von Willebrand disease (VWD) is the most common form, affecting 60% to 80% of individuals with the condition. It is available through hospitals, retail pharmacies, online pharmacies, and specialty pharmacies, serving various end users such as adults, pediatric, and geriatric patients.

The vonvendi or veyvondi market consists of sales of on-demand treatment and perioperative management. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.